{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:01:25Z","timestamp":1772136085054,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20fk0108502"],"award-info":[{"award-number":["20fk0108502"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["JPMH20HA1006"],"award-info":[{"award-number":["JPMH20HA1006"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["20A2003D"],"award-info":[{"award-number":["20A2003D"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["19A3001"],"award-info":[{"award-number":["19A3001"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In the present prospective study, 225 individuals in Kumamoto General Hospital, Japan, who received two-doses of BNT162b2 vaccine were enrolled\/followed up over 150\u00a0days and neutralizing activity (NT\n                    <jats:sub>50<\/jats:sub>\n                    ) of their sera and antiviral activity (EC\n                    <jats:sub>50<\/jats:sub>\n                    ) of IgG purified from sera on day-60 post-1st-dose were determined against wild-type SARS-CoV-2 (SARS-CoV-2\n                    <jats:sup>Wuhan<\/jats:sup>\n                    ) (n\u2009=\u2009211) and 9 variants (Alpha, Beta, Gamma, Delta, and Kappa) (n\u2009=\u200945). Time-dependent changes of IgG-activity (n\u2009=\u200925) against SARS-CoV-2\n                    <jats:sup>Wuhan<\/jats:sup>\n                    and variants were also examined. Day-60 sera showed reduced NT\n                    <jats:sub>50<\/jats:sub>\n                    by more than 50% against all variants examined, and greatest reduction was seen with Beta. IgG fractions of high-responders and moderate-responders showed similar fold-changes in EC\n                    <jats:sub>50<\/jats:sub>\n                    against each variant compared to SARS-CoV-2\n                    <jats:sup>Wuhan<\/jats:sup>\n                    . Evaluation of EC\n                    <jats:sub>50<\/jats:sub>\n                    of IgG obtained at different time-points (day-28 to -150) revealed time-dependent reduction of activity against all variants. However, against Delta, relatively long-lasting favorable antiviral activity (at least 150\u00a0days) was observed. Our data strongly suggest that the successful antecedent scale-up of mRNA-based vaccine administrations in Japan was the primary contributor to the lessening of the otherwise more devastating SARS-CoV-2 pandemic wave caused by the Delta variant. The present data that the effectiveness of vaccine against the then-dominant SARS-CoV-2 variant was likely associated with the moderation of the COVID-19 pandemic wave suggest that as in the case of influenza vaccines, the development of multivalent mRNA-based vaccines represent a generalizable approach to pre-emptively respond pandemic with mutable pathogens.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-17071-9","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T06:03:08Z","timestamp":1659938588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Neutralization activity of sera\/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants"],"prefix":"10.1038","volume":"12","author":[{"given":"Masayuki","family":"Amano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Otsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Omata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"17071_CR1","unstructured":"World Health Organization. Coronavirus Disease (COVID-19) Outbreak Situation (2022). https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---22-february-2022 Accessed 22 Feb 2022."},{"key":"17071_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265\u2013269 (2020).","journal-title":"Nature"},{"key":"17071_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"17071_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.35772\/ghm.2020.01040","volume":"2","author":"H Mitsuya","year":"2020","unstructured":"Mitsuya, H. & Kokudo, N. Sustaining containment of COVID-19: Global sharing for pandemic response. Glob. Health Med. 2, 53\u201355 (2020).","journal-title":"Glob. Health Med."},{"issue":"11","key":"17071_CR5","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S1473-3099(21)00263-2","volume":"21","author":"R Dal-R\u00e9","year":"2021","unstructured":"Dal-R\u00e9, R. et al. Ongoing and future COVID-19 vaccine clinical trials: Challenges and opportunities. Lancet Infect. Dis. 21(11), e342\u2013e347 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"17071_CR6","unstructured":"Pfizer. News \/ Pfizer and BioNTech. Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints (2021).https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine Accessed 28 Sept 2021."},{"key":"17071_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"17071_CR8","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"17071_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.35772\/ghm.2021.01010","volume":"3","author":"DD Richman","year":"2021","unstructured":"Richman, D. D. COVID-19 vaccines: Implementation, limitations and opportunities. Glob. Health Med. 3, 1\u20135 (2021).","journal-title":"Glob. Health Med."},{"key":"17071_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"17071_CR11","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","volume":"9","author":"D Hillus","year":"2021","unstructured":"Hillus, D. et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: A prospective cohort study. Lancet Respir. Med. 9, 1255 (2021).","journal-title":"Lancet Respir. Med."},{"key":"17071_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","volume":"398","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial. Lancet 398, 856\u2013869 (2021).","journal-title":"Lancet"},{"key":"17071_CR13","unstructured":"Johnson & Johnson. Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use\u2014First Single-Shot Vaccine in Fight Against Global Pandemic  (2021). https:\/\/www.jnj.com\/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic Accessed 28 Sept 2021."},{"key":"17071_CR14","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N. Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"key":"17071_CR15","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827 (2020).","journal-title":"Cell"},{"key":"17071_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","volume":"27","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, 620\u2013621 (2021).","journal-title":"Nat. Med."},{"key":"17071_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","volume":"593","author":"S Cele","year":"2021","unstructured":"Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 593, 142\u2013146 (2021).","journal-title":"Nature"},{"issue":"13","key":"17071_CR18","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 covid-19 vaccine. N. Engl. J. Med. 385(13), 1172\u20131183 (2021).","journal-title":"N. Engl. J. Med."},{"key":"17071_CR19","unstructured":"Novavax. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial (2021). https:\/\/www.globenewswire.com\/news-release\/2021\/01\/28\/2166253\/0\/en\/Novavax-COVID-19-Vaccine-Demonstrates-89-3-Efficacy-in-UK-Phase-3-Trial.html Accessed 28 Sept 2021."},{"key":"17071_CR20","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","volume":"384","author":"V Shinde","year":"2021","unstructured":"Shinde, V. et al. Efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1899\u20131909 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"17071_CR21","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","volume":"184","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184(9), 2384\u20132393 (2021).","journal-title":"Cell"},{"key":"17071_CR22","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","volume":"397","author":"EC Wall","year":"2021","unstructured":"Wall, E. C. et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 397, 2331\u20132333 (2021).","journal-title":"Lancet"},{"issue":"16","key":"17071_CR23","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","volume":"184","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184(16), 4220\u20134236 (2021).","journal-title":"Cell"},{"key":"17071_CR24","doi-asserted-by":"publisher","first-page":"22848","DOI":"10.1038\/s41598-021-01930-y","volume":"11","author":"K Maeda","year":"2021","unstructured":"Maeda, K. et al. Correlates of neutralizing\/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. Sci. Rep. 11, 22848 (2021).","journal-title":"Sci. Rep."},{"issue":"15","key":"17071_CR25","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1056\/NEJMc2102017","volume":"384","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum. N. Engl. J. Med. 384(15), 1466\u20131468 (2021).","journal-title":"N. Engl. J. Med."},{"key":"17071_CR26","unstructured":"Japanese Ministry of Health, Labour and Welfare. Visualizing the Data: Information on COVID-19 Infections. https:\/\/covid19.mhlw.go.jp\/extensions\/public\/en\/index.html. Accessed 7 Nov 2021."},{"key":"17071_CR27","unstructured":"Prime Minister\u2019s Office of Japan. COVID-19 Vaccines. https:\/\/www.kantei.go.jp\/jp\/headline\/kansensho\/vaccine.html Accessed 7 Nov 2021."},{"issue":"1","key":"17071_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41541-021-00420-6","volume":"6","author":"S Chivukula","year":"2021","unstructured":"Chivukula, S. et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. NPJ Vaccines 6(1), 153 (2021).","journal-title":"NPJ Vaccines"},{"key":"17071_CR29","doi-asserted-by":"publisher","first-page":"884433","DOI":"10.3389\/fimmu.2022.884433","volume":"13","author":"M Yu","year":"2022","unstructured":"Yu, M. et al. Design of a recombinant multivalent epitope vaccine based on SARS-CoV-2 and its variants in immunoinformatics approaches. Front. Immunol. 13, 884433 (2022).","journal-title":"Front. Immunol."},{"key":"17071_CR30","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1073\/pnas.2002589117","volume":"117","author":"S Matsuyama","year":"2020","unstructured":"Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. U.S.A. 117, 7001\u20137003 (2020).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"17071_CR31","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.1038\/s41598-021-84733-5","volume":"11","author":"K Maeda","year":"2021","unstructured":"Maeda, K. et al. Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. Sci. Rep. 11, 5563 (2021).","journal-title":"Sci. Rep."},{"issue":"4","key":"17071_CR32","doi-asserted-by":"publisher","first-page":"e01833","DOI":"10.1128\/mBio.01833-20","volume":"11","author":"SI Hattori","year":"2020","unstructured":"Hattori, S. I. et al. GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection. MBio 11(4), e01833\u2013e01920 (2020).","journal-title":"MBio"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17071-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17071-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17071-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:40:28Z","timestamp":1669336828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17071-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["17071"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-17071-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1463966\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"assertion":[{"value":"18 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13524"}}